meglumine - CISMeF

Preferred Label : meglumine;

MeSH definition : 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.;

MeSH synonym : methylglucamine;

MeSH CAS label : D-Glucitol, 1-deoxy-1-(methylamino)-;

MeSH Related Number : 6284-40-8 (Meglumine);

Registry Number MeSH : 6284-40-8;

Wikipedia link : https://en.wikipedia.org/wiki/Meglumine;

Codes EINECS : 228-506-9;

Is substance : O;

UNII : 6HG8UB2MUY;

InChIKey : MBBZMMPHUWSWHV-BDVNFPICSA-N;

Détails

Origin ID

D008536;

UMLS CUI

C0025179;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- meglumine [Substance BNPC]
Pharmacological action(s)
- contrast media [MeSH Descriptor]
Record concept(s)
- meglumine [MeSH concept]
Related MeSH Supplementary Concept(s)
- 1,2-distearylglycerate-3-N-methylglucamine [MeSH Supplementary Concept]
- 1-stearyl-2-behenylglycerate-3-N-methylglucamine [MeSH Supplementary Concept]
- 1-stearyl-2-myristylglycerate-3-N-methylglucamine [MeSH Supplementary Concept]
- N-methylglucamine gluconate [MeSH Supplementary Concept]
- PD 134308 [MeSH Supplementary Concept]
- PD 135158 [MeSH Supplementary Concept]
- PD 140.548 N-methyl-D-glucamine [MeSH Supplementary Concept]
- UTEN [MeSH Supplementary Concept]
- antimony-N-methylglucamine [MeSH Supplementary Concept]
- chromium(III)bis(N-(2,6-diethylphenylcarbamoylmethyl)iminodiacetic acid)meglumine [MeSH Supplementary Concept]
- dysprosium diethylenetriamine pentaacetic acid dimeglumine [MeSH Supplementary Concept]
- funixin meglumine [MeSH Supplementary Concept]
- gadobenic acid [MeSH Supplementary Concept]
- gadolinium DOTA meglumine [MeSH Supplementary Concept]
- gadoterate meglumine [MeSH Supplementary Concept]
- iocarmate meglumine [MeSH Supplementary Concept]
- meglumine acetrizoate [MeSH Supplementary Concept]
- meglumine cyclic adenylate [MeSH Supplementary Concept]
- meglumine-eicosapentaenoic acid formulation [MeSH Supplementary Concept]
- methylglucamine orotate [MeSH Supplementary Concept]
- penta-O-acetyl-N-chloro-N-methylglucamine [MeSH Supplementary Concept]
- pentagastrin meglumine [MeSH Supplementary Concept]
- reamberin [MeSH Supplementary Concept]
Semantic type(s)
- Indicator, Reagent, or Diagnostic Aid [UMLS semantic type]
- Organic Chemical [UMLS semantic type]
UMLS correspondences (same concept)
- Meglumine [NCIt concept]
- Meglumine (substance) [SNOMED CT concept]
- meglumine [Substance BNPC]
Validated automatic mappings to BTNT
- Meglumine antimonate [ICD-11 Extension code]

Position du mot-clé dans l'(les) arborescence(s) :

Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients